Clinical Applications of Integrative Analysis of Validated Somatic and Germline Genomic Results in Oncology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 25 April 2026 | Viewed by 3171

Special Issue Editor


E-Mail Website
Guest Editor
Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA
Interests: precision oncology; clinical genomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The aim of this Special Issue is to give a platform to studies that utilize and demonstrate the value of an integrated approach combining validated somatic (tumor) and germline (constitutional) genomic data for clinical management of cancer and precision oncology. Somatic and germline analysis has been reported to be beneficial in personalized therapeutic practice, tumorigenesis and cancer progression, inference on germline allele penetrance, and gene discovery. However, clinical applications of the integration of somatic and germline data are not routinely published. Signature somatic genomic profiles such as loss of heterozygosity (LOH), mismatch repair (MMR) status (i.e., MMR deficient or proficient), microsatellite instability (MSI), and tumor-derived information such as immunohistochemistry (IHC) of target proteins have unique values that can shed light on the role of germline genetic variants in disease. The understanding of genome findings from the somatic workflow can be much enhanced when performed in the context of patients’ constitutional genetic data. Conversely, the full extent of the consequence of germline findings, both in cancer susceptibility and therapy, can be elucidated when examined with somatic genetic data in unison.

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Special Issue.

Dr. Arezou A. Ghazani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor and constitutional genome integration
  • clinical application of somatic and germline findings
  • precision oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

28 pages, 959 KiB  
Article
Advancing Precision Oncology in Hereditary Paraganglioma-Pheochromocytoma Syndromes: Integrated Interpretation and Data Sharing of the Germline and Tumor Genomes
by Huma Q. Rana, Diane R. Koeller, McKenzie Walker, Busra Unal, Alison Schwartz Levine, Anu Chittenden, Raymond A. Isidro, Connor P. Hayes, Monica D. Manam, Ryan M. Buehler, Danielle K. Manning, Justine A. Barletta, Jason L. Hornick, Judy E. Garber, Arezou A. Ghazani and INT2GRATE Oncology Consortium
Cancers 2024, 16(5), 947; https://doi.org/10.3390/cancers16050947 - 26 Feb 2024
Cited by 2 | Viewed by 2588
Abstract
Standard methods of variant assessment in hereditary cancer susceptibility genes are limited by the lack of availability of key supporting evidence. In cancer, information derived from tumors can serve as a useful source in delineating the tumor behavior and the role of germline [...] Read more.
Standard methods of variant assessment in hereditary cancer susceptibility genes are limited by the lack of availability of key supporting evidence. In cancer, information derived from tumors can serve as a useful source in delineating the tumor behavior and the role of germline variants in tumor progression. We have previously demonstrated the value of integrating tumor and germline findings to comprehensively assess germline variants in hereditary cancer syndromes. Building on this work, herein, we present the development and application of the INT2GRATE|HPPGL platform. INT2GRATE (INTegrated INTerpretation of GeRmline And Tumor gEnomes) is a multi-institution oncology consortium that aims to advance the integrated application of constitutional and tumor data and share the integrated variant information in publicly accessible repositories. The INT2GRATE|HPPGL platform enables automated parsing and integrated assessment of germline, tumor, and genetic findings in hereditary paraganglioma–pheochromocytoma syndromes (HPPGLs). Using INT2GRATE|HPPGL, we analyzed 8600 variants in succinate dehydrogenase (SDHx) genes and their associated clinical evidence. The integrated evidence includes germline variants in SDHx genes; clinical genetics evidence: personal and family history of HPPGL-related tumors; tumor-derived evidence: somatic inactivation of SDHx alleles, KIT and PDGFRA status in gastrointestinal stromal tumors (GISTs), multifocal or extra-adrenal tumors, and metastasis status; and immunohistochemistry staining status for SDHA and SDHB genes. After processing, 8600 variants were submitted programmatically from the INT2GRATE|HPPGL platform to ClinVar via a custom-made INT2GRATE|HPPGL variant submission schema and an application programming interface (API). This novel integrated variant assessment and data sharing in hereditary cancers aims to improve the clinical assessment of genomic variants and advance precision oncology. Full article
Show Figures

Figure 1

Back to TopTop